ALX Oncology Holdings Inc.
General ticker "ALXO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $54.9M (TTM average)
ALX Oncology Holdings Inc. follows the US Stock Market performance with the rate: 44.6%.
Estimated limits based on current volatility of 3.8%: low 1.62$, high 1.74$
Factors to consider:
- Total employees count: 80 (+11.1%) as of 2024
- Top business risk factors: Significant losses, Dependence on lead product, Clinical trial uncertainties, High cost and complexity of clinical trials, Regulatory and compliance
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.86$, 2.73$]
- 2026-12-31 to 2027-12-31 estimated range: [0.84$, 2.56$]
Financial Metrics affecting the ALXO estimates:
- Positive: with PPE of -0.7 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -116.41 <= 0.07
- Positive: 42.60 < Shareholder equity ratio, % of 44.00 <= 64.25
- Positive: Investing cash flow per share per price, % of 114.26 > -0.65
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 2.22 <= 3.29
- Negative: negative Industry operating cash flow (median)
Short-term ALXO quotes
Long-term ALXO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $170.28MM | $142.47MM | $100.85MM |
| Operating Income | $-170.28MM | $-142.47MM | $-100.85MM |
| Non-Operating Income | $9.47MM | $7.62MM | $-0.85MM |
| Interest Expense | $1.56MM | $1.73MM | $1.60MM |
| R&D Expense | $141.79MM | $116.37MM | $77.00MM |
| Income(Loss) | $-160.81MM | $-134.85MM | $-101.69MM |
| Profit(Loss)* | $-160.81MM | $-134.85MM | $-101.69MM |
| Stockholders Equity | $189.71MM | $113.62MM | $25.98MM |
| Assets | $242.55MM | $147.78MM | $59.05MM |
| Operating Cash Flow | $-130.36MM | $-121.91MM | $-84.14MM |
| Capital expenditure | $1.27MM | $0.45MM | $0.21MM |
| Investing Cash Flow | $44.66MM | $86.26MM | $82.59MM |
| Financing Cash Flow | $59.29MM | $30.82MM | $0.36MM |
| Earnings Per Share** | $-3.74 | $-2.58 | $-1.90 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.